2021 Pipeline Guide for Leber’s Hereditary Optic Neuropathy: Drugs In Development – ResearchAndMarkets.com

2021 Pipeline Guide for Leber’s Hereditary Optic Neuropathy: Drugs In Development – ResearchAndMarkets.com




2021 Pipeline Guide for Leber’s Hereditary Optic Neuropathy: Drugs In Development – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 2, 1, 3, 2, 1, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy.
  • The pipeline guide reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leber’s Hereditary Optic Neuropathy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy

Key Topics Covered:

  • Leber’s Hereditary Optic Neuropathy (Leber Optic – Overview
  • Leber’s Hereditary Optic Neuropathy (Leber Optic – Therapeutics Assessment
  • Leber’s Hereditary Optic Neuropathy (Leber Optic – Companies Involved in Therapeutics Development
  • Leber’s Hereditary Optic Neuropathy (Leber Optic – Drug Profiles
  • Leber’s Hereditary Optic Neuropathy (Leber Optic – Dormant Projects
  • Leber’s Hereditary Optic Neuropathy (Leber Optic – Discontinued Products
  • Leber’s Hereditary Optic Neuropathy (Leber Optic – Product Development Milestones

Companies Mentioned

  • Alkeus Pharmaceuticals Inc
  • Antoxis Ltd
  • Astellas Pharma Inc
  • Biovista Inc
  • GenSight Biologics SA
  • Ixchel Pharma LLC
  • Khondrion BV
  • Metro International Biotech LLC
  • Mitobridge Inc
  • Mitotech SA
  • Neurophth Therapeutics Inc
  • Neuroptika Inc
  • PYCTX Ltd
  • Santhera Pharmaceuticals Holding AG
  • Stealth BioTherapeutics Corp

For more information about this report visit https://www.researchandmarkets.com/r/9qu6d6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900